Aldeyra Therapeutics, Inc.
ALDX
$1.86
$0.031.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.38% | -30.46% | -45.25% | -6.43% | 8.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.78% | -50.42% | -43.53% | 11.00% | 171.87% |
| Operating Income | 59.78% | 50.42% | 43.53% | -11.00% | -171.87% |
| Income Before Tax | 59.13% | 49.13% | 42.03% | -22.86% | -232.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.13% | 49.13% | 42.03% | -22.86% | -232.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.13% | 49.13% | 42.03% | -22.86% | -232.61% |
| EBIT | 59.78% | 50.42% | 43.53% | -11.00% | -171.87% |
| EBITDA | 60.02% | 50.62% | 43.68% | -11.07% | -173.80% |
| EPS Basic | 59.52% | 49.63% | 42.63% | -21.91% | -230.39% |
| Normalized Basic EPS | 59.53% | 49.65% | 42.61% | -21.88% | -230.28% |
| EPS Diluted | 59.52% | 49.63% | 42.63% | -21.91% | -230.39% |
| Normalized Diluted EPS | 59.53% | 49.65% | 42.61% | -21.88% | -230.28% |
| Average Basic Shares Outstanding | 0.98% | 1.00% | 1.06% | 0.80% | 0.65% |
| Average Diluted Shares Outstanding | 0.98% | 1.00% | 1.06% | 0.80% | 0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |